
    
      This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2
      week Safety Follow Up Period.

      Final eligibility will be determined at the Baseline Visit. Eligible patients will be
      randomized to receive placebo or SYN120 100 mg once a day (QD).
    
  